Form 4: Regulus Therapeutics Director Reports Full Share and Option Disposal Following Novartis Acquisition

A director of Regulus Therapeutics Inc. has reported the complete disposal of all common stock and stock options following the company's acquisition by Novartis AG, which closed on June 25, 2025, for $7.00 cash plus a contingent value right per share.

Summary

• Regulus Therapeutics Inc. (RGLS) was acquired by Novartis AG through its wholly-owned, indirect subsidiary, Redwood Merger Sub Inc.
• The merger agreement was dated April 29, 2025, and the merger became effective on June 25, 2025, with Regulus Therapeutics Inc. continuing as a wholly-owned subsidiary of Novartis AG.
• Shareholders of Regulus Therapeutics Inc. received an Offer Price of $7.00 in cash per share (the "Closing Amount") plus one Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive an additional $7.00 in cash upon the achievement of a specified milestone, subject to the terms of a CVR Agreement.
• Director Alice Shih-hou Huang disposed of all her direct and indirect beneficial ownership in Regulus Therapeutics common stock and stock options as a result of the merger.
• Common stock holdings, including 5,208 direct shares, 57,292 direct shares, 27,377 indirect shares (by spouse), and 57,292 indirect shares (by spouse), were tendered in exchange for the Offer Price.
• Restricted stock units were canceled and converted into cash equal to the Closing Amount per underlying share, plus one CVR per underlying share.
• In-the-Money Stock Options (exercise price less than $7.00) were canceled and converted into cash (Closing Amount minus exercise price) plus one CVR per underlying share.
• Out-of-the-Money Stock Options (exercise price equal to or greater than $7.00 but less than $14.00) were canceled and converted into one CVR per underlying share, with potential for cash payment if the CVR milestone is met.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders who received a cash payment and a CVR, indicating a successful acquisition. However, the CVR introduces some uncertainty, preventing a higher score.

Positives

• Shareholders received an immediate cash payment of $7.00 per share at the closing of the merger.
• Shareholders also received a Contingent Value Right (CVR) per share, offering potential for an additional $7.00 cash payment upon the achievement of a specified milestone.
• The merger provides a clear exit strategy and liquidity for Regulus Therapeutics shareholders, transitioning the company into a subsidiary of a major pharmaceutical entity.

Negatives

• Regulus Therapeutics Inc. ceases to be an independent publicly traded company, becoming a wholly-owned subsidiary of Novartis AG.
• The full potential value of $14.00 per share is contingent on future milestones, introducing uncertainty regarding the total consideration received from the CVR.
• Stock options with exercise prices equal to or greater than $14.00 would not receive any value from the CVR, though none are explicitly listed for the reporting person in this filing.

Risks

• The Contingent Value Right (CVR) payment of $7.00 is contingent upon the achievement of a specific milestone, meaning the full $14.00 per share consideration is not guaranteed.
• No payments will be made with respect to Out-of-the-Money Options if the CVR milestone payment is not made.

Future Outlook

The future outlook for Regulus Therapeutics Inc. is as a wholly-owned subsidiary of Novartis AG, with its former public shareholders now holding cash and contingent value rights tied to a future milestone. The success of the CVR payment depends on the achievement of a specific milestone, which is not detailed in this filing.

Industry Context

This acquisition reflects a continuing trend of larger pharmaceutical companies acquiring smaller biotechnology firms, particularly those with promising pipelines or platforms, to bolster their portfolios. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards, especially for assets in clinical development.

Comparison to Industry Standards

• The use of a CVR in this acquisition is a common practice in the biotechnology and pharmaceutical industry, particularly for deals involving companies with assets in development where future success is uncertain.
• Similar CVR structures have been seen in acquisitions like Bristol Myers Squibb's acquisition of MyoKardia or Sanofi's acquisition of Principia Biopharma, where a portion of the deal value was tied to clinical or regulatory milestones.
• The $7.00 cash upfront plus a $7.00 CVR structure provides immediate liquidity while allowing shareholders to participate in potential future upside, aligning with typical risk-sharing models in such transactions.

Management Changes

Stakeholder Impact

• Shareholders: Received $7.00 cash per share and one CVR per share, providing liquidity and potential future upside.
• Employees: Not directly addressed in this Form 4, but typically, mergers can lead to integration challenges or changes in employment.
• Customers/Suppliers: Not directly addressed, but the change in ownership may impact future business relationships.
• Creditors: Not directly addressed, but the company's financial obligations would now be backed by Novartis AG.

Next Steps

• Achievement of the milestone specified in the CVR Agreement, which would trigger the additional $7.00 cash payment per CVR.

Key Dates

Keywords

Regulus Therapeutics Inc., RGLS, Novartis AG, Merger, Acquisition, SEC Form 4, Beneficial Ownership, Contingent Value Right, CVR, Stock Options, Biotechnology, Pharmaceuticals